Puma Biotechnology (PBYI) Expected to Release Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) will likely be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Puma Biotechnology to post earnings of $0.04 per share and revenue of $53.00 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.09. The business had revenue of $44.81 million for the quarter, compared to analysts’ expectations of $42.00 million. Puma Biotechnology had a net margin of 10.69% and a return on equity of 20.30%. On average, analysts expect Puma Biotechnology to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Puma Biotechnology Price Performance

Shares of Puma Biotechnology stock opened at $7.80 on Wednesday. The firm has a 50 day simple moving average of $7.73 and a 200 day simple moving average of $7.14. Puma Biotechnology has a fifty-two week low of $3.05 and a fifty-two week high of $8.75. The firm has a market cap of $397.02 million, a P/E ratio of 16.25 and a beta of 1.22.

Insider Buying and Selling

In related news, Director Adrian Senderowicz sold 27,000 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $7.20, for a total value of $194,400.00. Following the transaction, the director directly owned 27,000 shares in the company, valued at $194,400. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Allison Dorval sold 11,610 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $7.20, for a total transaction of $83,592.00. Following the completion of the transaction, the director directly owned 90,780 shares in the company, valued at approximately $653,616. The trade was a 11.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 132,028 shares of company stock worth $1,006,711. 22.20% of the stock is currently owned by company insiders.

Institutional Trading of Puma Biotechnology

Institutional investors have recently bought and sold shares of the business. Barclays PLC lifted its stake in shares of Puma Biotechnology by 1.9% in the 4th quarter. Barclays PLC now owns 81,434 shares of the biopharmaceutical company’s stock valued at $485,000 after purchasing an additional 1,553 shares during the period. Cerity Partners LLC grew its stake in shares of Puma Biotechnology by 18.2% during the fourth quarter. Cerity Partners LLC now owns 12,072 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 1,862 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Puma Biotechnology by 39.7% during the third quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 2,290 shares during the period. First Trust Advisors LP increased its holdings in Puma Biotechnology by 2.5% in the fourth quarter. First Trust Advisors LP now owns 122,800 shares of the biopharmaceutical company’s stock valued at $731,000 after purchasing an additional 3,021 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in Puma Biotechnology by 3.8% in the first quarter. Royal Bank of Canada now owns 85,999 shares of the biopharmaceutical company’s stock valued at $254,000 after purchasing an additional 3,117 shares during the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Wall Street Analyst Weigh In

PBYI has been the topic of a number of recent research reports. Wall Street Zen lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. Weiss Ratings cut Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company has an average rating of “Hold”.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.